Psilocybin and Your Heart: What You Need to Know

Psilocybin temporarily raises blood pressure and, to a lesser extent, heart rate in nearly everyone who takes it. In supervised clinical settings with pre-screened healthy participants, these spikes are generally modest, peak around 60 to 90 minutes after dosing, and fade within four to six hours without medical treatment. But the phrase “generally modest” does a lot of heavy lifting, and the story gets more complicated once you factor in pre-existing heart conditions, other medications, repeated use, and the unpredictability of unsupervised settings.

What Happens to Blood Pressure and Heart Rate During a Session

The most consistent cardiovascular effect of psilocybin is a rise in blood pressure, particularly systolic (the top number). A narrative review of clinical data found that, on average, systolic blood pressure climbs roughly 19 mmHg and diastolic blood pressure about 9 mmHg after a standard therapeutic dose.¹ To put that in perspective, that is similar to the blood pressure bump you might see during moderate exercise or a stressful argument. The peak tends to hit about 60 to 90 minutes after swallowing the capsule and generally resolves within four to six hours.

Heart rate effects are smaller and less predictable. In a safety study examining 113 psilocybin administrations across a range of doses (15 to 30 mg), a heart rate above 100 beats per minute was observed in only about 7% of sessions.² That same study found that half of all sessions produced a systolic reading above 140 mmHg at some point, but severe hypertension (above 180 mmHg systolic) was never recorded in the dataset. These were healthy volunteers in a controlled environment, which matters when you try to generalize.

A pooled analysis of 14 clinical studies offered a more granular picture of how often blood pressure really spikes high. Systolic pressure exceeded 170 mmHg in about 6% of sessions, with a median duration of roughly 8.5 minutes. It crossed 180 mmHg in about 3% of sessions. Only two sessions out of more than 500 met criteria for severe hypertension (systolic above 180 and diastolic above 120 at the same time), and only one session in the entire dataset required blood-pressure-lowering medication. That single case involved a participant whose baseline blood pressure was already elevated, who reached a systolic of 214 mmHg after a high dose. He was given nitroglycerin, came down, and was sent home on schedule with no lasting effects.³

The QT Interval Question

Beyond blood pressure, researchers have looked at whether psilocybin affects the heart’s electrical rhythm, specifically a measurement called the QTc interval. When the QTc stretches too long, it can in rare cases predispose a person to dangerous heart rhythm disturbances. A dedicated study of psilocybin’s effect on QTc found a real but shallow relationship between psilocin (the active metabolite) concentration in the blood and QTc prolongation. At a standard 25 mg dose, the average QTc change was about 2 milliseconds, which is clinically trivial. The analysis estimated that the threshold considered potentially concerning (a 10-millisecond increase) would not be reached until blood concentrations of psilocin exceeded what a normal dose produces.⁴

That said, a cardiovascular safety review noted that a QTc prolongation greater than 60 milliseconds from baseline was seen in two participants given 25 mg psilocybin in at least one trial, which is a more noteworthy shift.⁵ Whether those were outliers or signals of individual susceptibility is not clear, but it is one reason clinical protocols typically screen out people who already have a prolonged QTc or who take medications known to lengthen it.

How Psilocybin Compares to Other Psychedelics

Psilocybin is not the only psychedelic that nudges the cardiovascular system, and it is useful to know where it falls relative to others. A double-blind crossover study that gave the same people both psilocybin and LSD found that psilocybin pushed blood pressure higher, while LSD pushed heart rate higher. When researchers calculated the rate-pressure product, a rough index of how hard the heart is working, the two substances were comparable.⁶ A three-way comparison that added mescaline to the mix found all three substances produced moderate autonomic effects; the only statistically significant difference was that psilocybin caused a larger increase in diastolic blood pressure than LSD.⁷ In practical terms, psilocybin’s cardiovascular footprint is in the same ballpark as other classic psychedelics, not dramatically safer or riskier.

Why Anxiety During the Trip Matters for Your Heart

Blood pressure during a psilocybin session is not purely pharmacological. Psychological distress can amplify the physical response. A pilot study of psilocybin-assisted therapy in older long-term AIDS survivors found that four participants developed self-limited severe hypertension during the session, and the spikes waxed and waned in tandem with anxiety symptoms.⁸ In other words, the moments of fear or paranoia that can occur during a psychedelic experience appear to layer their own hemodynamic surge on top of whatever the drug is already doing. A study of veterans with severe PTSD reported that heart rate and blood pressure stayed within safe limits throughout their sessions, with the highest systolic reading reaching 166 mmHg, but these participants received careful psychological support designed to minimize distress.⁹

This interaction between the psychedelic experience and cardiovascular response also surfaces in the most dramatic case report in the literature. A case of takotsubo cardiomyopathy, sometimes called “broken heart syndrome,” was documented after a person ingested Psilocybe semilanceata mushrooms. The authors proposed that the psychedelic’s psychological effects, such as heightened paranoia or hallucinations, may have acted as an emotional trigger for the syndrome, which involves a temporary ballooning of part of the heart’s ventricle in response to a catecholamine surge.¹⁰ Takotsubo is extremely rare in any context, but the case illustrates that intense psychological stress during a trip is not just uncomfortable; it has real cardiac implications.

Drug Interactions That Change the Risk

The cardiovascular picture shifts when psilocybin is combined with other medications. A scoping review of antidepressant-psychedelic combinations found no cases of serotonin syndrome across the studies examined, but it did find that the SSRI escitalopram significantly blunted psilocybin’s blood pressure and pupil effects. Paroxetine, another SSRI, reduced LSD’s heart rate increase compared to placebo.¹¹ So SSRIs, if anything, appear to dampen the cardiovascular response rather than worsen it.

Monoamine oxidase inhibitors (MAOIs) are a different story. A case report described a 42-year-old man who took one gram of Psilocybe cubensis mushrooms while on tranylcypromine (an MAOI) and extended-release amphetamine. About half an hour later he developed severe hypertension with chest pain and palpitations, and his electrocardiogram showed ST-elevation consistent with a heart attack. Emergency catheterization found no blocked arteries, and he recovered after overnight hospitalization. The authors suspected the culprit was not psilocybin itself but phenylethylamine, a trace amine found in Psilocybe cubensis mushrooms, which can cause dangerous blood pressure spikes when combined with an MAOI and a stimulant like amphetamine.¹² This case is a reminder that consuming whole mushrooms introduces compounds beyond psilocybin, and the interaction profile is different from pharmaceutical-grade psilocybin.

The Valve Concern With Repeated Use

If you have read anything about psychedelics and heart valves, the concern traces back to a receptor called 5-HT2B. Drugs that strongly and chronically activate this receptor on heart valve tissue can promote abnormal growth of fibrous tissue on the valves, eventually causing them to stiffen and leak. This is what happened with fenfluramine, the appetite suppressant pulled from the market in the 1990s. Psilocybin’s active metabolite, psilocin, does bind to 5-HT2B, and lab work has confirmed that its binding potency there can equal or exceed its potency at the 5-HT2A receptor, which is the primary target responsible for the psychedelic experience.¹³

The critical detail, though, is how hard psilocin pushes that receptor compared to known valve-damaging drugs. An exposure-response model found that psilocin activates 5-HT2B at only about 52% of the maximum signal that serotonin itself can produce, making it a partial agonist. By comparison, norfenfluramine, the metabolite of fenfluramine that destroyed valves, reaches about 96% of that maximum.¹⁴ Because a partial agonist can never exceed its ceiling no matter how much you take, psilocin is fundamentally incapable of driving valve signaling as hard as a full agonist can.

For occasional full-dose use, this is reassuring. The concern becomes more relevant with microdosing, where people take small amounts on a recurring schedule over months. A review comparing psychedelics to known cardiotoxic drugs concluded that chronic microdosing could carry a risk of valve fibrosis that has not yet been adequately studied. The authors noted that even weekly use of MDMA, another partial 5-HT2B agonist, has been linked to valve abnormalities when maintained for several years, and that duration of exposure plays a major role in drug-induced valve disease.¹⁵ An animal study using LSD as a proxy (which has a similar 5-HT2B profile to psilocybin) found that eight weeks of microdosing in mice using a common human-equivalent schedule produced no detectable cardiac pathology.¹⁶ The short answer is that a handful of full-dose sessions is unlikely to stress your valves, but nobody has long-term human data on what years of regular microdosing does.

Older Adults and People With Heart Disease

Almost everything we know about psilocybin’s cardiovascular effects comes from studies that excluded people with significant heart conditions. A review focused on older adults pointed out that very few participants over 65, or with serious cardiovascular comorbidities, have been enrolled in psychedelic trials, making it hard to say how safe psilocybin is for the populations most likely to have high blood pressure, stiff arteries, or reduced cardiac reserve.¹⁷ A 19-point rise in systolic pressure is unremarkable in a healthy 30-year-old. In someone whose resting systolic pressure is already 160 mmHg and whose arteries are calcified, that same bump could push them into territory where stroke risk becomes real.

A narrative review of cardiovascular safety emphasized that risk interpretation changes substantially with cardiovascular comorbidity, interacting medications, repeated exposure, and the use of non-standardized mushroom products, whose active-alkaloid content can vary by more than tenfold.¹ That last point is easy to overlook. If you are eating whole mushrooms rather than a measured pharmaceutical capsule, you may be getting twice or half the dose you expected, along with other bioactive compounds like phenylethylamine that carry their own cardiovascular effects.

What Happens Outside Clinical Walls

The reassuring safety data from clinical trials reflects a specific scenario: a pre-screened healthy person taking a known dose in a calm environment with trained guides and medical equipment nearby. Real-world use is messier. An analysis of poison center data between 2000 and 2016 found that tachycardia (rapid heart rate) was among the most commonly reported effects of psilocybin-mushroom exposures, appearing in about 18% of cases. Serious outcomes were uncommon but did include cardiac arrest, along with hyperthermia and seizures.¹⁸ These cases involve self-reported doses of unknown potency, frequent polysubstance use, and people with unknown medical histories, so they tell you more about worst-case scenarios than about psilocybin’s intrinsic risk.

A separate case report described a man who experienced cardiac arrest after consuming psilocybin mushrooms. He was later found to have hereditary hemochromatosis, a condition that causes iron to build up in the heart and other organs. His troponin levels (a marker of heart muscle damage) were markedly elevated. The case illustrates how a pre-existing condition that a person might not even know about can turn an otherwise manageable cardiovascular stress into a serious event.¹⁹

Changes in Heart Rate Variability

Researchers have begun looking beyond simple blood pressure and heart rate to subtler measures of cardiac autonomic control. A study tracking heart rate dynamics under several psychedelics found that psilocybin increased not only mean heart rate but also heart rate variability and a measure of heart rate entropy, which reflects how complex and irregular the beat-to-beat pattern is.²⁰ This is an emerging line of research and the clinical significance is still unclear. Increased heart rate variability is often considered a sign of healthy autonomic flexibility, but interpreting it during a pharmacologically altered state is a different matter entirely. The interaction between psychedelics and the autonomic nervous system is acknowledged in the field as poorly understood and in need of a more systematic research framework.²¹

Practical Takeaways If You Are Considering Psilocybin

For someone with a healthy heart, normal blood pressure, and no interacting medications, the acute cardiovascular effects of a single psilocybin dose in a supervised setting are transient and have not produced lasting harm in any published trial. The blood pressure rise is real but short-lived, the heart rate change is modest, and the QT effect at standard doses is minimal.

The gaps in the evidence are where the risk actually lives. If you have uncontrolled high blood pressure, a history of heart disease, or a condition like hypertrophic cardiomyopathy, you are walking into a drug-induced blood pressure spike with a cardiovascular system that has less margin for error, and you are doing it with essentially no trial data to guide expectations. If you take an MAOI, the combination with whole mushrooms (not just psilocybin) has produced at least one hypertensive emergency serious enough to mimic a heart attack. If you are microdosing on a regular schedule over months or years, the valve question is open and unresolved, with theoretical concern but limited human data. And if you are using mushrooms of unknown species and potency outside a medical setting, you are adding dosing uncertainty, polysubstance risk, and the absence of medical monitoring to the equation.

Clinical trials screen participants heavily, exclude anyone with meaningful cardiovascular risk, control the dose down to the milligram, and keep a physician nearby. Every layer of that safety architecture that gets removed adds a layer of cardiac risk that the published literature has not characterized.